Boehringer Ingelheim to distribute Synvisc in France:
This article was originally published in Clinica
Executive Summary
Boehringer Ingelheim has won exclusive distribution rights to Synvisc in France, Algeria, Morocco and Tunisia. The viscosupplementation treatment for osteoarthritis of the knee was developed by US company Biomatrix and is based on its hylan technology. Under the terms of the agreement, which is valid for up to 15 years, Biomatrix, which is based in Ridgefield, New Jersey, will receive a licensing fee of up to $8 million, including up-front fees and milestone payments. German pharmaceutical company Boehringer Ingelheim intends to launch the product in France in early 1997.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.